LYRA - Lyra Therapeutics Forward Price-to-Revenue Multiple

Corporate company logo of Lyra Therapeutics Inc (LYRA)

Against the backdrop of risks regarding final test failures and dependence on a single platform, the daily chart on GURU.Markets reflects the forward P/S dynamics of Lyra Therapeutics, Inc. (LYRA), where the 1.40 metric determines the parameter status. While its reputation as an ENT innovator strengthens physician confidence, the current portfolio rebalancing following sinusitis setbacks is forcing the business to optimize expenses and seek new niches.

LYRA lyratherapeutics.com: Forward Price to Sales in the range 07/04/2022 - 03/28/2026

Comprehensive metric breakdowns and analytics for Lyra Therapeutics (LYRA)

- market price and analyst price targets:
General company analysis:Lyra Therapeutics, Inc LYRA
Manufactured products of lyratherapeutics.com

The forward P/S reflects the market value of the business relative to its expected sales, allowing for an assessment of the premium paid for potential growth. By analyzing the projected P/S of Lyra Therapeutics, Inc. (LYRA), an investor compares the current market capitalization with the estimated revenue from the commercialization of LYR-210 systems, which is critical for the biotech sector where company valuation is based on future success in treating chronic rhinosinusitis.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|RANI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Synergy CHC SNYR|RLYB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lexaria (LEXX)|Price-to-Projected Revenue Ratio Pulmatrix|Market Cap to Projected Revenue PTHL (ftzy.com.cn)|Forward P/S Multiple APM|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP